ArticleOphthalmology and therapy2026
Twelve-Month Visual, Refractive, and Ocular Wavefront Outcomes of SmartSight KLEx, Pooling Original and NOVA Workflows, on the SCHWIND ATOS: A Single-Surgeon Cohort Study.
Article in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo report the visual, refractive, astigmatic, and ocular higher-order aberration (HOA) outcomes of keratorefractive lenticule extraction (KLEx) with the SCHWIND ATOS femtosecond laser platform in a large single-surgeon cohort.
methodsIn this retrospective consecutive series, 2518 eyes of 1292 patients underwent single-surgeon KLEx (SmartSight procedure, SCHWIND ATOS platform) for myopia or myopic astigmatism. Data from two treatment workflows were pooled: the original SmartSight lenticule workflow (1886 eyes) and, from 2025, SmartSight NOVA with CenTrax-assisted centration (632 eyes); workflow-stratified outcomes are reported separately in Table 4. Refraction, uncorrected and corrected distance visual acuity ( (UDVA and CDVA, respectively), and pyramidal-wavefront aberrometry (OSIRIS-T corneal topographer and ocular aberrometer; 4 and 6 mm) were recorded for 12 months of follow-up (primary; 3 months secondary). The target was emmetropia; astigmatism used the Alpins vector method. Denominators were endpoint specific, and inference was clustered by patient.
resultsMean preoperative spherical equivalent (SEQ) was - 3.86 ± 1.93 diopters (D). At 12 months post-procedure, in 830 eyes with a complete acuity record and 930 with paired SEQ, mean SEQ was - 0.04 ± 0.31 D, with 92.9% within ± 0.50 D and 98.2% within ± 1.00 D; achieved correction tracked attempted (slope 0.98). UDVA was 20/20 or better in 94.9% of eyes, and 94% saw uncorrected at least as well as preoperatively corrected. One of 830 eyes lost exactly two CDVA lines; none lost more than two. Astigmatic outcomes are documentation dependent: among eyes with an explicitly recorded postoperative cylinder, 68.6% were within 0.50 D, whereas the whole-cohort estimate (89.9%) rests on the unvalidated convention that a blank cylinder field denotes plano, and postoperative axis was not captured, so vector indices are exploratory. Paired mean SEQ changes from month 3 through month 12 were < 0.05 D. An enhancement-as-failure composite (any enhancement before 12 months counted as failure) was met by 89.6% of eyes. In a paired wavefront subset (412 eyes), HOA induction was modest and coma-dominated: total ocular HOA rose from 0.14 to 0.18 µm at 4 mm (P < 0.001) and was not significantly changed at 6 mm (P = 0.10). Preoperative spherical aberration was positive; ocular spherical aberration decreased modestly while total corneal spherical aberration was preserved at 12 months (P = 0.59).
conclusionIn this large single-surgeon series, pooling data from the original SmartSight workflow and the SmartSight NOVA, KLEx on the SCHWIND ATOS delivered accurate, safe, and stable 12-month outcomes with excellent uncorrected vision and only modest higher-order aberration induction. As a single-surgeon experience using an evolving offset and two treatment workflows that are temporally confounded with each other and with surgical experience, these findings describe a descriptive association between the offset strategy and favorable outcomes rather than validation of a fixed nomogram or of SmartSight NOVA specifically; the current + 0.75 D offset was not represented at one year and requires prospective, workflow-controlled validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.